Select Page

References

Filter by Reference Type

Filter by Condition

Filter by Doctor

NX-13-1B (Landos Biopharma)
NX-13

Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Active Ulcerative Colitis
Inclusion criteria: endoscopically and clinically active UC, failed biologics or Biologic naïve (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)
Exclusion criteria: use of immunosuppressant (6-MP, azathioprine, methotrexate) within 25 days, treatment with Tofacitinib (Xeljanz) within 4 weeks, positive for C Difficile, Hepatitis B or C, HIV, surgical procedure requiring general anesthesia within 1 month or planned elective surgery, positive COVID-19 test within the past 6 months
Status: Enrolling

BT-11-202B (Landos Biopharma)
Omilancor (BT-11) vs. Humira (Adalimumab)

Study Drug administration: Oral and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease
Inclusion criteria: endoscopically and clinically active CD, failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve
Exclusion criteria: abscesses, bowel resection or diversion within 6 months, positive for C. Difficile in past 4 months, HIV, Hepatitis B or Hepatitis C
Status: Enrolling

Request Your Appointment Today